RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación
Artículo científico (JournalArticle)
Bioorthogonal Photoactivation of 2-Nitrobenzyl Caged Doxorubicin Anticancer Prodrugs on Gold Nanostars
[EN] Bioorthogonal chemistry that can be controlled through near-infrared (NIR) light is a promising route to therapeutics. This study proposes a method to intracellularly photoactivate prodrugs using plasmonic gold nanostars (AuNSt) and NIR irradiation. Two strategies are followed. On one hand, doxorubicin (Dox) masked with a 2-nitrobenzyl carbamate (proDox1) is used as a photoactivatable prodrug. In the second strategy, a photolabile Dox prodrug (proDox2) obtained by modification of Dox with 2-nitrobenzyl diol bearing a disulfide is attached to the AuNSt surface. Under NIR irradiation AuNSt induce local electromagnetic field enhancement, leading to photocleavage of the 2-nitrobenzyl moiety in both proDox1 and proDox2, and subsequent Dox release. Near field enhancement by excitation of surface plasmons in AuNSt is sufficient to record the surface-enhanced Raman scattering (SERS) spectra of proDox1 and proDox2. The therapeutic potential of this bioorthogonal photoactivation strategy is confirmed in vitro and in vivo using a mouse model of human melanoma. NIR-activated AuNSt induce in vivo the intracellular release of Dox and subsequent cancer cell death, thus reducing tumor growth at low irradiation power density to avoid undesired photothermal effects. These results demonstrate that AuNSt are suitable platforms for NIR light-triggered drug delivery in cancer therapy., This research was supported by project PID2021-126304OB-C41 and PID2021-128141OB-C22 funded by MCIN/AEI/10.13039/501100011033/and by European Regional Development Fund-A way of doing Europe. The work was also supported by Generalitat Valenciana (CIPROM/2021/007). This study was also supported by the ERC Advanced Grant Edison (101052997). This research was supported by CIBER-Consorcio Centro de Investigacion Biomedica en Red-(CB06/01/2012), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion. J. J. E-M. thanks the financial support from FC AECC and especially to the AECC Council of Valencia for the trust placed (PRDVA21651ESTE). O.F.S. acknowledges the support from the Provincial Council of Gipuzkoa under the program Fellows Gipuzkoa. The authors thank the UPV electron microscopy and CIPF confocal and electron microscopy services for technical support.
Proyecto:
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-126304OB-C41
,
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-128141OB-C22
,
European Commission / HE 101052997
,
Generalitat Valenciana CIPROM/2021/007
,
Asociación Española Contra el Cáncer PRDVA21651ESTE
,
Centro de Investigación Biomédica en Red CB06/01/2012